Maze Therapeutics, Inc.
corporate_fare Company Profile
Maze Therapeutics, Inc. (NASDAQ:MAZE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for MAZE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MAZE spans 10-Q, 8-K, 424B5, 10-K.
Recent high-impact activity:
- Maze Q3 Loss Widens to $48M, Missing Estimates on R&D Costs
- Vertex Kidney Drug Data Sparks 22% Surge in Maze Therapeutics
- Maze Therapeutics Q2 2026: Net Loss Widens to $44.7M, Cash Runway Extended with $494.9M in Reserves
- Maze Therapeutics Q2 2026: Wider Loss Offset by Pipeline Progress and Cash Runway into 2029
- Q1 Net Loss Beats Estimates, $144.7M Offering & $20M Milestone Extend Cash Runway
Financial Snapshot
Short Interest & Short Volume
8.76 days to coverFINRA reported short interest of 6,684,604 shares in MAZE as of the October 30, 2026 settlement, a 11.2% decrease from the prior period — about 8.8 days to cover at its recent average daily volume. On November 20, 2026, 65.4% of MAZE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.